Incendia Therapeutics, Inc.
Incendia Therapeutics is a clinical-stage biotechnology company focused on discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve cancer treatment outcomes. Their approach targets the structural and biochemical underpinnings of the TME to enable immune cells and immuno-oncology therapeutics to reach their targets, aiming to redefine the treatment landscape for recalcitrant cancers.
Industries
Incendia Therapeutics, Inc.
Boston, Massachusetts, United States, North America
Products
Investigational anti-DDR1 monoclonal antibody
An investigational monoclonal antibody that binds and inhibits Discoidin Domain Receptor 1 (DDR1) to remodel the tumor microenvironment and enable immune cell access; under clinical evaluation in early-phase oncology trials with planned pivotal development.
Investigational anti-DDR1 monoclonal antibody
An investigational monoclonal antibody that binds and inhibits Discoidin Domain Receptor 1 (DDR1) to remodel the tumor microenvironment and enable immune cell access; under clinical evaluation in early-phase oncology trials with planned pivotal development.
Expertise Areas
- Antibody therapeutics development
- Tumor microenvironment biology
- Immuno-oncology
- Early-phase clinical trial management
Key Technologies
- Monoclonal antibody therapeutics
- Spatial transcriptomics
- Whole-slide image analysis (computational pathology)
- Biomarker discovery and translational assays